EVAX
Income statement / Annual
Last year (2023), Evaxion Biotech A/S's total revenue was $73,112.00,
and the percentage change from the previous year is not available.
In 2023, Evaxion Biotech A/S's net income was -$22.13 M.
See Evaxion Biotech A/S’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$73,112.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$571,319.00 |
$343,452.00 |
$105,719.00 |
$80,984.00 |
$73,928.00 |
| Gross Profit |
$73,112.00 |
-$571,319.00 |
-$343,452.00 |
-$105,719.00 |
-$80,984.00 |
-$73,928.00 |
| Gross Profit Ratio |
1 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$11.92 M
|
$17.06 M
|
$19.58 M
|
$10.90 M
|
$8.22 M
|
$3.73 M
|
| General & Administrative
Expenses |
$10.35 M
|
$8.21 M
|
$6.25 M
|
$5.67 M
|
$2.63 M
|
$1.88 M
|
| Selling & Marketing
Expenses |
-$275,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$10.35 M
|
$8.21 M
|
$6.25 M
|
$5.67 M
|
$2.63 M
|
$1.88 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$16,000.00 |
$15,000.00 |
| Operating Expenses |
$22.27 M |
$25.26 M |
$25.83 M |
$16.57 M |
$10.86 M |
$5.63 M |
| Cost And Expenses |
$22.27 M |
$25.26 M |
$25.83 M |
$16.57 M |
$10.86 M |
$5.63 M |
| Interest Income |
$154,000.00 |
$2.83 M |
$2.04 M |
$216,000.00 |
$9,000.00 |
$2,000.00 |
| Interest Expense |
$897,000.00 |
$1.51 M |
$915,000.00 |
$223,000.00 |
$1.22 M |
$698,000.00 |
| Depreciation &
Amortization |
$615,000.00
|
$571,319.00
|
$343,452.00
|
$105,719.00
|
$80,984.00
|
$73,928.00
|
| EBITDA |
-$21.40 M
|
-$22.58 M
|
-$24.17 M
|
-$16.46 M
|
-$11.90 M
|
-$6.18 M
|
| EBITDA Ratio |
-292.74 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-303.6
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$718,000.00
|
$1.32 M
|
$1.12 M
|
-$7,000.00
|
-$1.16 M
|
-$636,933.00
|
| Income Before Tax |
-$22.92 M |
-$23.94 M |
-$24.71 M |
-$16.58 M |
-$12.02 M |
-$6.27 M |
| Income Before Tax Ratio
|
-313.42
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$791,215.00 |
-$772,000.00 |
-$178,000.00 |
-$1.56 M |
-$825,000.00 |
-$735,000.00 |
| Net Income |
-$22.13 M |
-$23.17 M |
-$24.53 M |
-$15.02 M |
-$11.20 M |
-$5.54 M |
| Net Income Ratio |
-302.62 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-8.11 |
-9.8 |
-12.58 |
-9.27 |
-6.91 |
-2.88 |
| EPS Diluted |
-8.11 |
-9.8 |
-12.58 |
-9.27 |
-6.91 |
-2.88 |
| Weighted Average Shares
Out |
$2.73 M
|
$2.36 M
|
$1.95 M
|
$1.62 M
|
$1.62 M
|
$1.92 M
|
| Weighted Average Shares
Out Diluted |
$2.73 M
|
$2.36 M
|
$1.95 M
|
$1.62 M
|
$1.62 M
|
$1.92 M
|
| Link |
|
|
|
|
|
|
